Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro

C Paindelli, N Navone, CJ Logothetis, P Friedl… - Biomaterials, 2019 - Elsevier
C Paindelli, N Navone, CJ Logothetis, P Friedl, E Dondossola
Biomaterials, 2019Elsevier
Mechanistic analysis of metastatic prostate cancer (PCa) biology and therapy response
critically depends upon clinically relevant three-dimensional (3D) bone-like, organotypic
culture. We here combine an engineered bone-mimetic environment (BME) with longitudinal
microscopy to test the growth and therapy response of 3D PCa tumoroids. Besides
promoting both tumor-cell autonomous and microenvironment-dependent growth in PCa cell
lines and patient-derived xenograft cells, the BME enables in vivo-like tumor cell response to …
Abstract
Mechanistic analysis of metastatic prostate cancer (PCa) biology and therapy response critically depends upon clinically relevant three-dimensional (3D) bone-like, organotypic culture. We here combine an engineered bone-mimetic environment (BME) with longitudinal microscopy to test the growth and therapy response of 3D PCa tumoroids. Besides promoting both tumor-cell autonomous and microenvironment-dependent growth in PCa cell lines and patient-derived xenograft cells, the BME enables in vivo-like tumor cell response to therapy, and reveals bone stroma dependent resistance to chemotherapy and BME-targeted localization and induction of cytoxicity by Radium-223. The BME platform will allow the propagation, compound screening and mechanistic dissection of patient-derived bone tumor isolates and applications toward personalized medicine.
Elsevier